Our formula may help improve cholesterol levels and blood pressure, promoting long-term cardiovascular well-being
These success stories can serve as motivation for others considering the therapy
Just two weeks later, on 1 April 2026, the FDA approved Foundayo, Eli Lillys brand name for orforglipron, making it the first small-molecule, non-peptide oral GLP-1 receptor agonist approved for chronic weight management
It cycles between reduced (GSH) and oxidized (GSSG) forms to preserve cellular oxidative homeostasis
Our physicians design customized treatment schedules that may range from single courses to periodic interventions with comprehensive monitoring throughout
Reach out to Registered Dietitian, Janyce, at [email protected] for personalized support!